News Room

All Press Releases In The News Blogs
11 Aug 2026
Press Release
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia 
10 Jun 2026
In The News
Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease 
26 May 2026
Press Release
Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention 
Curevo - Acquired by Eli Lilly - (NYSE:LLY)
21 Sep 2026
Press Release
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) 
New Amsterdam (NASDAQ:NAMS)
27 Apr 2026
Press Release
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders 
Centessa Pharmaceuticals - Acquired by Eli Lilly - (NYSE: LLY)
19 Feb 2026
In The News
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases 
Altesa BioSciences
20 Jan 2026
Press Release
GSK enters agreement to acquire RAPT Therapeutics 
RAPT Therapeutics - Acquired by GSK (LON:GSK)
07 Jan 2026
Press Release
Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody 
Ottimo Pharma
10 Dec 2025
Press Release
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs 
14 Nov 2025
Press Release
Medicxi Announces €500 Million Fund V
08 Sep 2025
Press Release
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder 
Kaerus Bioscience Limited - Acquired by Servier
22 Jul 2025
Press Release
Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion 
ViceBio - Acquired by Sanofi (EURONEXT:SAN)
23 May 2025
Press Release
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib 
Fore Biotherapeutics
14 May 2025
Press Release
Kaerus Bioscience’s lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) 
Kaerus Bioscience Limited - Acquired by Servier
07 May 2025
Press Release
Altesa BioSciences Details Positive Topline Vapendavir Results from Phase 2 Placebo-Controlled Rhinovirus Challenge Study in COPD Patients 
Altesa BioSciences
27 Mar 2025
Press Release
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata 
Alys Pharmaceuticals
17 Mar 2025
Press Release
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine 
12 Mar 2025
Press Release
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology 
Rivus Pharmaceuticals, Inc
11 Mar 2025
Press Release
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome 
Kaerus Bioscience Limited - Acquired by Servier
04 Feb 2025
Press Release
Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology 
Alys Pharmaceuticals
08 Jan 2025
Press Release
RAPT Therapeutics Announces $150 Million Private Placement
RAPT Therapeutics Announces $150 Million Private Placement 
19 Dec 2024
Press Release
Ottimo Pharma Raises over $140 Million in Series A Financing 
Ottimo Pharma
28 Oct 2024
Press Release
Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody 
23 Sep 2024
Press Release
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine 
10 Sep 2024
Press Release
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers 
Centessa Pharmaceuticals - Acquired by Eli Lilly - (NYSE: LLY)
27 Aug 2024
Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT 
Vaderis Therapeutics AG
14 Aug 2024
Press Release
Rivus Pharmaceuticals' Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure 
Rivus Pharmaceuticals, Inc
06 Aug 2024
Press Release
Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis 
25 Jul 2024
Press Release
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome 
21 May 2024
Genmab Completes Acquisition of ProfoundBio 
08 Apr 2024
Press Release
Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments 
08 Apr 2024
Press Release
Medicxi Announces $40m investment in D3 Bio
03 Apr 2024
Press Release
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio 
ProfoundBio - Acquired by Genmab (NASDAQ:GMAB)
23 Feb 2024
Press Release
Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline 
30 Nov 2023
Press Release
Levicept Appoints Eliot Forster as CEO 
Levicept
27 Jul 2023
Press Release
Medicxi Announces $400m Medicxi IV
17 Jul 2023
Press Release
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
30 Mar 2023
Press Release
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases 
Granular Therapeutics Limited (an Alys company)
16 Mar 2023
Press Release
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
28 Nov 2022
Press Release
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease 
New Amsterdam (NASDAQ:NAMS)
03 Oct 2022
Press Release
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody 
Villaris - Acquired by Incyte (NASDAQ:INCY)
22 Aug 2022
Press Release
Backed by Medicxi, Novartis vets launch rare blood disorder biotech with fresh take on drug class used in cancers 
Vaderis Therapeutics AG
04 Aug 2022
Press Release
Medicxi portfolio company MiroBio to be acquired by Gilead Sciences for approximately $405 million 
29 Jun 2022
Press Release
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases 
03 May 2022
Press Release
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) 
Phathom Pharmaceuticals (NASDAQ: PHAT)
09 Feb 2022
Press Release
Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants 
Rivus Pharmaceuticals, Inc
09 Feb 2022
Press Release
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD) 
Phathom Pharmaceuticals (NASDAQ: PHAT)
08 Sep 2021
Press Release
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor 
Xenikos
27 Jul 2021
Press Release
Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers 
Kurome Therapeutics - Acquired by an undisclosed company
20 Jul 2021
Press Release
Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases 
Rivus Pharmaceuticals, Inc
28 May 2021
Press Release
Centessa Announces Pricing of Initial Public Offering 
Centessa Pharmaceuticals - Acquired by Eli Lilly - (NYSE: LLY)
22 Apr 2021
Press Release
Monopteros Therapeutics Initiates Clinical Trial to Reprogram Regulatory T Cells in Solid Tumors 
22 Mar 2021
Press Release
Aura Biosciences Announces Oversubscribed $80 Million Financing 
Aura - (NASDAQ: AURA)
16 Feb 2021
Press Release
Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model 
19 Nov 2020
Press Release
SynOx Therapeutics raises €37M in Series A Financing 
25 Sep 2020
Press Release
PALLADIO COMPLETES $20 MILLION SERIES B FINANCING 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
22 Sep 2020
Press Release
Medicxi announces the closing of its first €200 million Secondary Fund, led by Pantheon with co-lead LGT Capital Partners
19 Aug 2020
Press Release
First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency 
Z Factor - Centessa Therapeutics (NASDAQ:CNTA)
15 May 2020
Blog
Operation Warp Speed – Moncef Slaoui’s mission to deliver a COVID-19 vaccine
by Francesco De Rubertis
17 Mar 2020
Press Release
Medicxi Bolsters and Expands Team with Senior Industry Leaders
07 Feb 2020
Press Release
What is Villaris Therapeutics and how will it help my vitiligo? 
Villaris - Acquired by Incyte (NASDAQ:INCY)
18 Dec 2019
Press Release
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial 
Xenikos
09 Dec 2019
Press Release
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting 
Xenikos
22 Oct 2019
Press Release
ApcinteX Starts Clinical Trial of Novel Haemophilia Drug 
ApcinteX - Centessa Therapeutics (NASDAQ:CNTA)
14 Oct 2019
Press Release
Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease 
Xenikos
18 Sep 2019
Press Release
Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature 
Divide and Conquer
19 Jul 2019
Press Release
Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters
08 Jul 2019
Press Release
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH" 
Breakpoint Therapeutics
04 Jun 2019
Press Release
Yukin Therapeutics raises €3.3 million to develop new cancer treatments 
Yukin Therapeutics
15 May 2019
Press Release
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals 
Phathom Pharmaceuticals (NASDAQ: PHAT)
13 May 2019
Press Release
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs 
Minerva Neurosciences (NASDAQ: NERV)
02 Apr 2019
Press Release
Aura Biosciences Completes $40 Million Series D Financing 
Aura - (NASDAQ: AURA)
02 Apr 2019
Press Release
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol 
Molecular Partners (S​wiss​: MOLN.SW)
04 Feb 2019
In The News
Endpoints News
Medicxi bankrolls the launch of a pair of biotech twins focused on orexins for narcolepsy and more 
20 Dec 2018
Press Release
Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard® in acute graft-versus-host disease 
Xenikos
19 Dec 2018
Press Release
Molecular Partners and Amgen announce Strategic Collaboration in Immuno-Oncology 
Molecular Partners (S​wiss​: MOLN.SW)
18 Dec 2018
Press Release
Morphogen-IX raises £18.4M ($23.2M) in a Series B financing 
Morphogen-IX - Centessa Therapeutics (NASDAQ:CNTA)
12 Dec 2018
Press Release
GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
12 Dec 2018
Press Release
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 
Synthorx - Acquired by Sanofi (EURONEXT:SAN)
28 Nov 2018
Press Release
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain 
Minerva Neurosciences (NASDAQ: NERV)
27 Nov 2018
Press Release
Morphogen-IX Announces MGX292 as Clinical Development Candidate 
Morphogen-IX - Centessa Therapeutics (NASDAQ:CNTA)
19 Nov 2018
Press Release
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers 
Minerva Neurosciences (NASDAQ: NERV)
31 Oct 2018
Press Release
Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products 
Egalet (NASDAQ:EGLT)
30 Oct 2018
Press Release
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET) 
ObsEva (NASDAQ: OBSV)
01 Oct 2018
Blog
Medicxi Expands the Partners Group
by Francesco De Rubertis
28 Sep 2018
Press Release
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain 
ObsEva (NASDAQ: OBSV)
13 Sep 2018
Press Release
GenSight Biologics provides an update on the clinical and regulatory pathways for GS010 
Gensight (Euronext: SIGHT)
22 Aug 2018
Press Release
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF) 
Minerva Neurosciences (NASDAQ: NERV)
25 Jul 2018
Press Release
ObsEva Expands Executive Team Hiring a Chief Commercial Officer 
ObsEva (NASDAQ: OBSV)
19 Jul 2018
In The News
Endpoints News
Gilead brings Medicxi’s tiny Gadeta into the cell therapy fold, hunting a way to pick the lock on solid tumors 
19 Jul 2018
Press Release
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration 
Molecular Partners (S​wiss​: MOLN.SW)
19 Jul 2018
Press Release
Business Wire
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors 
28 Jun 2018
In The News
Newswire
Morphogen-Ix Appoints CEO and Forms Global Scientific Advisory Board 
21 Jun 2018
Press Release
Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 
Molecular Partners (S​wiss​: MOLN.SW)
20 Jun 2018
In The News
L'Echo
'Investir dans les biotechs en Belgique? Une question de temps' 
12 Jun 2018
Press Release
GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
07 Jun 2018
Press Release
Egalet Appoints Industry Veteran John Varian to Board of Directors 
Egalet (NASDAQ:EGLT)
07 Jun 2018
Press Release
SutroVax Announces $85M Series C Financing led by TPG Growth 
Vaxcyte (NASDAQ:PCVX)
29 May 2018
Press Release
Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
17 May 2018
Press Release
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia 
Minerva Neurosciences (NASDAQ: NERV)